脂肪酸代谢相关长非编码RNA分析用于识别低级别胶质瘤预后标志物并预测免疫治疗反应
本研究利用癌症基因组图谱数据,聚焦脂肪酸代谢相关长非编码RNA,通过Cox回归构建低级别胶质瘤风险评分模型。共获得14个预后相关长非编码RNA,模型在预测不同风险患者预后方面表现出良好效度和信度,其中GHET-1与化疗敏感性相关,高风险患者呈现T辅助细胞介导的免疫抑制。
要点
- 基于脂肪酸代谢相关长非编码RNA构建的低级别胶质瘤风险模型表现出良好效度和信度。
- 共识别14个预后相关长非编码RNA,其中GHET-1与低级别胶质瘤化疗敏感性相关。
- 高风险患者呈现T辅助细胞介导的免疫抑制,可能为免疫治疗提供新路径。
核心结论
- 聚焦长非编码RNA调控与脂肪酸代谢重编程,本研究建立了创新的低级别胶质瘤预后预测模型,表现出良好效度和信度,为未来低级别胶质瘤治疗开发提供了新的分子和细胞靶点。
研究设计与样本
- 本研究采用癌症基因组图谱数据,聚焦关键脂肪酸代谢相关长非编码RNA,使用单因素/多因素及最小绝对收缩和选择算子Cox回归构建风险评分模型。
- 研究通过评估低级别胶质瘤免疫标志物与肿瘤耐药之间的关联,评价预后相关长非编码RNA在低级别胶质瘤进展中的作用,并进行功能富集分析。
主要发现
- 本研究共获得14个预后相关长非编码RNA。
- 风险模型表现出良好效度和信度,在不同风险的低级别胶质瘤患者中是更优的预后预测因子。
- 在识别的长非编码RNA中,GHET-1与低级别胶质瘤对当前化疗方案的敏感性显著相关,可能是影响低级别胶质瘤进展的关键长非编码RNA。
- 高风险患者表现出T辅助细胞介导的免疫抑制,可能为未来低级别胶质瘤免疫治疗开辟新路径。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-grade gliomas (LGGs) are notorious for their difficult early-stage diagnosis, limited treatment options, and poor prognosis, making them a focal point in cancer research. Long noncoding RNAs (lncRNAs) have been identified as regulators of metabolic reprogramming in tumor cells, offering new directions for LGG treatment. METHODS: This study employed data from The Cancer Genome Atlas, focusing on key fatty acid metabolism-related lncRNA. A risk scoring model was developed using univariate/multifactorial and least absolute shrinkage and selection operator Cox regression. Additionally, the study evaluated the role of these prognostic lncRNAs in LGG progression by assessing associations between LGG immune markers and tumor drug resistance. Finally, functional enrichment analysis highlighted the molecular roles of these lncRNAs. RESULTS: In this study, a total of 14 prognostic lncRNAs were obtained. The risk model demonstrated excellent validity and reliability, making it a superior predictor of prognosis among patients with varying LGG risks. Among the identified lncRNAs, GHET-1 was notably associated with LGG sensitivity to current chemotherapy options and might be a crucial lncRNA affecting LGG progression. High-risk patients exhibited T-helper cell-mediated immunosuppression, potentially paving new paths for future LGG immunotherapy. CONCLUSIONS: Focusing on lncRNA regulation and fatty acid metabolism reprogramming, this study established an innovative prognostic prediction model for LGGs, showing outstanding validity and reliability. The findings offer new molecular and cellular targets for the future development of LGG treatments.
引用
- Cui Y. Analysis of Long Noncoding RNA in Fatty Acid Metabolism to Identify Prognostic Markers and Predict Immunotherapy Response in Low-Grade Glioma. World Neurosurg. 2025. PMID: 39952400. doi:10.1016/j.wneu.2025.123723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。